IRLAB Therapeutics ABOSTO:IRLAB A -1.43%36 3-Year ROIIC % is 32.78 as of Dec. 2025, which is at its 10-year median of 32.78. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,320 Biotechnology companies, IRLAB Therapeutics AB ranks better than 68.94% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
IRLAB Therapeutics AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 32.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for IRLAB Therapeutics AB's 3-Year ROIIC % or its related term are showing as below:
OSTO:IRLAB A's 3-Year ROIIC % is ranked better than 68.94% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs OSTO:IRLAB A: 32.78
IRLAB Therapeutics AB (OSTO:IRLAB A) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
IRLAB Therapeutics AB 3-Year ROIIC % Related Terms
IRLAB Therapeutics AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for IRLAB Therapeutics AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IRLAB A vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's 3-Year ROIIC % falls into.
IRLAB Therapeutics AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -87.018 (Dec. 2025) - -113.223 (Dec. 2022) )
/
( 157.137 (Dec. 2025) - 77.183 (Dec. 2022) )
=
26.205
/
79.954
=
32.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a 3-Year ROIIC % of 32.78 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on IRLAB Therapeutics AB and its competitors. This is near median its historical median of 32.78. According to the industry distribution chart, IRLAB Therapeutics AB ranks #410 out of 1320 companies in the Biotechnology industry, placing it in the top 31.1%.
Is IRLAB Therapeutics AB's 3-Year ROIIC % too high?
IRLAB Therapeutics AB's current 3-Year ROIIC % of 32.78 is near median its 10-year median of 32.78. Based on the distribution chart, IRLAB Therapeutics AB ranks #410 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #410 out of 1320 companies for 3-Year ROIIC %. This puts IRLAB Therapeutics AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current 3-Year ROIIC % is 32.78, which is near median its own 10-year median of 32.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.74, compared to a current price of kr1.37 — trading 88.3% below its estimated fair value. The current 3-Year ROIIC % is 32.78, which is near median its 10-year median of 32.78. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current 3-Year ROIIC % is 32.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.37 is trading 88.3% below its estimated GF Value™ of kr11.74.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
3-Year ROIIC %: 32.78 (near median its 10-year median of 32.78)
GF Value™: kr11.74 vs. price of kr1.37 (88.3% below fair value)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score
Get the complete analysis for OSTO:IRLAB A
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
